Defiance’s Suite of Daily Options (0DTE) Income ETFs, $QQQY & $JEPY, Surpass $100M AUM in less than 30 Days
MIAMI–(BUSINESS WIRE)–$JEPY #ETFs–Defiance ETFs, a pioneering force in the world of thematic and income-based exchange-traded funds (ETFs), is... Read more.
NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, November 3
PORTLAND, Ore.–(BUSINESS WIRE)–Northwest Natural Holding Company (NYSE: NWN) (NW Natural Holdings) announced today it will issue its third quarter and... Read more.
Q4 DRAM Contract Prices Set to Rise, With Estimated Quarterly Increase of 3-8%, Says TrendForce
TAIPEI, Taiwan–(BUSINESS WIRE)–#DDR4—TrendForce reports indicate a universal price increase for both DRAM and NAND Flash starting in the fourth... Read more.
UnitedHealth Group Reports Third Quarter 2023 Results
Revenues of $92.4 Billion Grew 14% Year-Over-Year Earnings from Operations Grew 14% Cash Flows from Operations were $6.9 Billion Earnings were $6.24 Per Share, Adjusted... Read more.
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Phase 3 DELTA 2 results demonstrated that delgocitinib cream provided statistically significant improvements in both... Read more.
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA A post hoc four-year interim subgroup analysis of the ongoing ECZTEND open-label extension trial assessed whether continuous... Read more.
Almirall’s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on... Read more.
AM Best Europe Insurance Market Briefing to Examine State of Industry Amid Escalating Challenges; Beazley CEO to Deliver Keynote
LONDON–(BUSINESS WIRE)–#insurance—AM Best will host its annual Europe Insurance Market and Methodology Briefings on Tuesday, 7 November 2023, from... Read more.
SES Appoints Adel Al-Saleh as CEO
LUXEMBOURG–(BUSINESS WIRE)–Regulatory News: SES, a leading provider of global content connectivity solutions, today announced that Adel Al-Saleh has... Read more.
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023
TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced... Read more.